





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/082,123	02/26/2002	Daniel P. Getman	10-1765.00070 (2869/5)	8050
22907	7590 03/05/2003			
22707				

BANNER & WITCOFF

1001 G STREET N W SUITE 1100 WASHINGTON, DC 20001 EXAMINER

POWERS, FIONA

ART UNIT PAPER NUMBER

1626

DATE MAILED: 03/05/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	_				
,	Application No.	Applicant(s)			
Office Antion Occurrence	10/082,123	GETMAN ET AL.			
Office Action Summary	Examiner	Art Unit			
	Fiona T. Powers	1626			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILLING DATE OF THIS COMMUNICATION.  Estensions of time may be available under the provisions of 37 GPR 1.15  If the period for reply specified above, the manifum statutory period of the property specified above, the manifum statutory period of a reply specified above, the manifum statutory period of a failure to reply within the set or extended period for reply will, by statute.  Any reply received by the Office later than three months after the mailing seamed patient term adjustment. See 37 GPR 1.704(b).	16(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days till apply and will expire SIX (6) MONTHS from	ely filed s will be considered timely.			
Responsive to communication(s) filed on					
2a) ☐ This action is FINAL. 2b) ☑ This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims					
4) Claim(s) 1-11 is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) 1-11 is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or	election requirement.				
Application Papers					
9) The specification is objected to by the Examiner					
10)☐ The drawing(s) filed on is/are: a)☐ accep	ted or b) objected to by the Exam	niner.			
Applicant may not request that any objection to the		• • •			
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12)☐ The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority documents have been received.					
Certified copies of the priority documents have been received in Application No					
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) ☐ The translation of the foreign language prov 15)☐ Acknowledgment is made of a claim for domestic					
Attachment(s)					
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Review (PTO-948)     ✓ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 6.		(PTO-413) Paper No(s) atent Application (PTO-152)			

Application/Control Number: 10/082,123

Art Unit: 1626

Receipt is acknowledged of the preliminary amendment and disclosure statement filed February 26, 2002, which have been entered in the file.

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claim 5 is rejected under 35 U.S.C. 101 as claiming the same invention as that of claim 6 of prior U.S. Patent No. 5,705,500. This is a double patenting rejection.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969)

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1 to 4 and 6 to 11 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 to 5 and 7 to 12 of U.S. Patent No. 5,705,500. Although the conflicting claims are not identical.

Application/Control Number: 10/082,123 Page 3

Art Unit: 1626

they are not patentably distinct from each other because the claims overlap when the compounds are of the formula shown in claim 1 or a pharmaceutically acceptable salt thereof. The claims of the application and the patent differ from each other in that the claims of the application includes pharmaceutically acceptable prodrug or ester of the compound shown in claim 1 which are not included in the patent. They also differ in that the patent specifies that for R<sup>4</sup> the sulfonamide sulfur atom is bound to a carbon atom of the benzo ring and the application does not specify how the sulfonamide sulfur atom is bound to a carbon atom of the benzo ring. One of ordinary skill in the art would have been motivated to make the claimed compounds with the expectation that compounds useful as retroviral protease inhibitors would be obtained.

Claims 1 and 6 to 11 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 and 3 to 8 of U.S. Patent No. 6,169,085. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims overlap when n in the instant application is 1. The claims of the application and the patent differ from each other in that in the application there can be 0, 1 or 2 CH<sub>2</sub> radicals

Application/Control Number: 10/082,123

Art Unit: 1626

bound to the sulfur atom (n is 0, 1 or 2) and in the patent there is only one CH<sub>2</sub> radical bound to the sulfur atom. In addition, the claims of the application includes pharmaceutically acceptable prodrug or ester of the compound shown in claim 1 which are not included in the patent claims. One of ordinary skill in the art would have been motivated to make the claimed compounds with the expectation that compounds useful as retroviral protease inhibitors would be obtained.

The references made of record and not relied upon show the state of the art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Fiona T. Powers whose telephone number is 703-308-4535. The examiner can normally be reached on Monday - Friday 8:30 AM to 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph K. McKane can be reached on 703-308-4537. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Application/Control Number: 10/082,123 Page 5

Art Unit: 1626

Jiona T. Powers Fiona T. Powers Primary Examiner Art Unit 1626

ftp March 4, 2003